Souvenaid lacks evidence for slowing Alzheimer’s, NPS says
Souvenaid manufacturer Nutricia immediately said it “strongly refutes” the NPS’s conclusions, which “misrepresent… the clinical data available to support Souvenaid’s use in people with early Alzheimer’s disease”.
Last year the product was listed with state food authorities and touted as a significant breakthrough in early Alzheimer's disease treatment backed by clinical trials.
Two randomised controlled trials, funded by manufacturer Nutricia, showed the product improved memory over 24 weeks.
One trial of 259 drug-naive